IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A multilayer dosage form comprising

a) a neutral core,

b) an inner methacrylate copolymer coating comprising at least 90% by weight of (meth)acrylate monomers having neutral radicals, wherein the methacrylate copolymer has a minimum film-forming temperature as specified in DIN 53 787 not exceeding 30°C, and a pharmaceutically active substance bound to the methacrylate polymer ~~of a methaerylate copolymer~~

c) an outer coating of a copolymer which is comprised of 40 to 95% by weight free-radical polymerized C_1- to C_4-alkyl esters of acrylic or of methacrylic acid and 5 to 60% by weight (meth)acrylate monomers having an anionic group in the alkyl radical~~,~~

~~wherein~~

~~the inner coating consists substantially of a methacrylate copolymer which is comprised of at least 90% by weight of (meth)acrylate monomers having neutral radicals, has a minimum film-forming temperature as specified in DIN 53 787 not exceeding 30°C, and comprises the pharmaceutical active substance in bound form~~.

2. (Currently Amended) The multilayer dosage form as claimed in claim 1, wherein the methacrylate copolymer of the inner coating is polymerized from 25-35% by weight methyl methacrylate, 75 to 65% by weight ethyl acrylate and, ~~where appropriate~~ optionally, up to 10% by weight other vinylically polymerizable monomers, wherein the proportionate amounts add up to 100% by weight.

3. (Previously Presented) The multilayer dosage form as claimed in claim 1, wherein the active substance/polymer ratio of the inner layer is from 20:1 to 1:20.

4. (Currently Amended) The multilayer dosage form as claimed in claim 1, wherein the outer coating ~~consists substantially of~~ comprises a (meth)acrylate copolymer which is composed of of 40 to 60% by weight methacrylic acid and 60 to 40% by weight methyl methacrylate or

40 to 60% by weight methacrylic acid and 60 to 40% by weight ethyl acrylate.

5. (Currently Amended) The multilayer dosage form as claimed in claim 1, wherein the outer coating ~~consists substantially of~~ comprises a (meth)acrylate copolymer which is composed of 20 to 40% by weight methacrylic acid and 80 to 60% by weight methyl methacrylate.

6. (Currently Amended) The multilayer dosage form as claimed in claim 1, wherein the outer coating ~~consists substantially of~~ comprises a (meth)acrylate copolymer which is composed of 20 to 34% by weight methacrylic acid and/or acrylic acid, 20 to 69% by weight methyl acrylate, 0 to 40% by weight ethyl acrylate and, where appropriate, 0 to 10% by weight further vinylically copolymerizable monomers, wherein the glass transition temperature of the copolymer as specified in ISO 11357-2, subsection 3.3.3, does not exceed 60°C.

7. (Currently Amended) The multilayer dosage form as claimed in claim 1, wherein the outer coating ~~consists substantially of~~ comprises a (meth)acrylate copolymer

~~consisting~~ which is composed of 10 to 30% by weight methyl methacrylate, 50 to 70% by weight methyl acrylate and 5 to 15% by weight methacrylic acid.

8. (Previously Presented) The multilayer dosage form as claimed in claim 1, wherein said multilayer dosage form comprises an active substance from the active substance classes of aminosalicylates, of sulfonamides or of glucocorticoids.

9. (Previously Presented)The multilayer dosage form as claimed in claim 8, wherein said multilayer dosage form comprises the active substance 5-aminosalicylic acid, olsalazine, sulfalazine, prednisone, prednisolone or budesonide.

10. (Previously Presented)The multilayer dosage form as claimed in claim 1, wherein said multilayer dosage form comprises an active substance from the active substance classes of enzymes, peptide hormones, immunomodulatory proteins, antigens, antibodies or of oligonucleotides.

11. (Previously Presented)The multilayer dosage form as claimed in claim 10, wherein said multilayer dosage form comprises the active substance pancreatin, insulin, human growth hormone (hGH), corbaplatin, intron A, calcitonin, cromalyn, interferons, calcitonin, granulocyte colony stimulating factor (G-CSF), interleukin, parathyroid hormones, glucagon, pro-somatostatin, somatostatin, detirelix, cetrorelix, vasopressin, 1-deaminocysteine-8-D-arginine-vasopressin, leuprolide acetate or an antigen which has been isolated from one or more grasses or one or more other plants.

12. (Previously Presented) The multilayer dosage form as claimed in claim 1, wherein the values for the percentage release of active substance in a hypotonic and an isotonic release medium based on phosphate buffer pH 6.8 do not differ from one another at any time in the period from 1 to 5 hours by more than 10%.

13. (New) The multilayer dosage form as claimed in claim 1, wherein the inner coating comprises not more than 1% by weight of a release agent.

14. (New) The multilayer dosage form as claimed in claim 1, wherein the inner coating does not comprise release agents.

15. (New) The multilayer dosage form as claimed in claim 1, wherein the inner coating does not comprise plasticizer.

16. (New) The multilayer dosage form as claimed in claim 1, wherein the methacrylate copolymer comprise 65% by ethyl acrylate and 35% by weight methyl methacrylate.